TNF-Induced Target Cell Killing by CTL Activated through Cross-Presentation

Cell Reports

Volumn 2, Issue 3, 2012, Pages 478-487

  Wohlleber, Dirk ^a   Kashkar, Hamid ^b   Gärtner, Katja ^a   Frings, Marianne K ^a   Odenthal, Margarete ^b   Hegenbarth, Silke ^a   Börner, Carolin ^a   Arnold, Bernd ^c   Hämmerling, Günter ^c   Nieswandt, Bernd ^d   van Rooijen, Nico ^e   Limmer, Andreas ^a   Cederbrant, Karin ^f   Heikenwalder, Mathias ^g   Pasparakis, Manolis ^b   Protzer, Ulrike ^g   Dienes, Hans Peter ^b   Kurts, Christian ^a   Krönke, Martin ^b   Knolle, Percy A ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

^f ASTRAZENECA R AND D   (Sweden)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADENOVIRUS INFECTION; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVATION; IMMUNOSURVEILLANCE; LIVER CELL; LIVER SINUSOID; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIGEN PRESENTATION; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HEPATOCYTES; IMMUNITY, CELLULAR; IMMUNOLOGIC SURVEILLANCE; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE;

EID: 84866954276     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.08.001     Document Type: Article

References (42)

1. Allan R.S., Smith C.M., Belz G.T., van Lint A.L., Wakim L.M., Heath W.R., Carbone F.R. Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 2003, 301:1925-1928.
2. Ando K., Moriyama T., Guidotti L.G., Wirth S., Schreiber R.D., Schlicht H.J., Huang S.N., Chisari F.V. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med. 1993, 178:1541-1554.
3. Bowie A.G., Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 2008, 8:911-922.
4. Chung S.J., Kim J.K., Park M.C., Park Y.B., Lee S.K. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J. Rheumatol. 2009, 36:2416-2420.
5. Diehl L., Schurich A., Grochtmann R., Hegenbarth S., Chen L., Knolle P.A. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology 2008, 47:296-305.
6. Ermolaeva M.A., Michallet M.C., Papadopoulou N., Utermöhlen O., Kranidioti K., Kollias G., Tschopp J., Pasparakis M. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 2008, 9:1037-1046.
7. Farrell H.E., Vally H., Lynch D.M., Fleming P., Shellam G.R., Scalzo A.A., Davis-Poynter N.J. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997, 386:510-514.
8. Galea I., Bernardes-Silva M., Forse P.A., van Rooijen N., Liblau R.S., Perry V.H. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 2007, 204:2023-2030.
9. Gao B., Radaeva S., Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 2009, 86:513-528.
10. Giannandrea M., Pierce R.H., Crispe I.N. Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice. Hepatology 2009, 49:2010-2020.
11. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 2001, 19:65-91.
12. Heymann F., Meyer-Schwesinger C., Hamilton-Williams E.E., Hammerich L., Panzer U., Kaden S., Quaggin S.E., Floege J., Gröne H.J., Kurts C. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J. Clin. Invest. 2009, 119:1286-1297.
13. Holtappels R., Podlech J., Pahl-Seibert M.F., Jülch M., Thomas D., Simon C.O., Wagner M., Reddehase M.J. Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J. Exp. Med. 2004, 199:131-136.
14. Iannacone M., Sitia G., Isogawa M., Marchese P., Castro M.G., Lowenstein P.R., Chisari F.V., Ruggeri Z.M., Guidotti L.G. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat. Med. 2005, 11:1167-1169.
15. Jo J., Aichele U., Kersting N., Klein R., Aichele P., Bisse E., Sewell A.K., Blum H.E., Bartenschlager R., Lohmann V., Thimme R. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 2009, 136:1391-1401.
16. Klenerman P., Hill A. T cells and viral persistence: lessons from diverse infections. Nat. Immunol. 2005, 6:873-879.
17. Kurts C., Robinson B.W., Knolle P.A. Cross-priming in health and disease. Nat. Rev. Immunol. 2010, 10:403-414.
18. Lang K.S., Georgiev P., Recher M., Navarini A.A., Bergthaler A., Heikenwalder M., Harris N.L., Junt T., Odermatt B., Clavien P.A., et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006, 116:2456-2463.
19. Lang P.A., Contaldo C., Georgiev P., El-Badry A.M., Recher M., Kurrer M., Cervantes-Barragan L., Ludewig B., Calzascia T., Bolinger B., et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat. Med. 2008, 14:756-761.
20. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gewert D., Borrow P., Tough D.F. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 2003, 4:1009-1015.
21. Li S., Kaur P.P., Chan V., Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin. Rheumatol. 2009, 28:787-791.
22. Limmer A., Ohl J., Kurts C., Ljunggren H.G., Reiss Y., Groettrup M., Momburg F., Arnold B., Knolle P.A. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 2000, 6:1348-1354.
23. Limmer A., Ohl J., Wingender G., Berg M., Jüngerkes F., Schumak B., Djandji D., Scholz K., Klevenz A., Hegenbarth S., et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur. J. Immunol. 2005, 35:2970-2981.
24. Maini M.K., Boni C., Lee C.K., Larrubia J.R., Reignat S., Ogg G.S., King A.S., Herberg J., Gilson R., Alisa A., et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 2000, 191:1269-1280.
25. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
26. Nakanishi Y., Lu B., Gerard C., Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009, 462:510-513.
27. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006, 6:173-182.
28. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
29. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10:26-35.
30. Protzer U., Maini M.K., Knolle P.A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 2012, 12:201-213.
31. Reddehase M.J. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2002, 2:831-844.
32. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005, 5:215-229.
33. Savinov A.Y., Wong F.S., Stonebraker A.C., Chervonsky A.V. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J. Exp. Med. 2003, 197:643-656.
34. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
35. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
36. Schurich A., Böttcher J.P., Burgdorf S., Penzler P., Hegenbarth S., Kern M., Dolf A., Endl E., Schultze J., Wiertz E., et al. Distinct kinetics and dynamics of cross-presentation in liver sinusoidal endothelial cells compared to dendritic cells. Hepatology 2009, 50:909-919.
37. Semmling V., Lukacs-Kornek V., Thaiss C.A., Quast T., Hochheiser K., Panzer U., Rossjohn J., Perlmutter P., Cao J., Godfrey D.I., et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 2010, 11:313-320.
38. Sigal L.J., Crotty S., Andino R., Rock K.L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999, 398:77-80.
39. Sprinzl M.F., Oberwinkler H., Schaller H., Protzer U. Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier. J. Virol. 2001, 75:5108-5118.
40. Stabenow D., Frings M., Trück C., Gärtner K., Förster I., Kurts C., Tüting T., Odenthal M., Dienes H.P., Cederbrant K., et al. Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology 2010, 51:1430-1437.
41. Wu K.K., Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu. Rev. Med. 1996, 47:315-331.
42. Zhu J., Huang X., Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 2007, 81:3170-3180.